SLE linked to higher risk for 15 cancers in meta-analysis

  • Arthritis Res Ther

  • curated by Miriam Davis, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A meta-analysis finds that patients with systemic lupus erythematosus (SLE) may be at increased risk for 15 cancers, especially hematologic and digestive cancers.
  • The patients' overall cancer risk may be increased by 28%.

Why this matters

  • Increased cancer surveillance is indicated.

Study design

  • Meta-analysis of 24 studies (n>100,000) that met eligibility criteria after a search of PubMed, EMBASE, and Web of Science.
  • Funding: None.

Key results

  • SLE was associated with increased incidence (vs general population) of these cancers:
    • Overall cancers, pooled standardized incidence rate (SIR): 1.28 (95% CI, 1.16-1.42) with similar rates for males and females.
    • Non-Hodgkin's lymphoma, pooled SIR: 4.93 (95% CI, 3.81-6.36).
    • Hodgkin's lymphoma, pooled SIR: 2.60 (95% CI, 2.14-3.17).
    • Leukemia, pooled SIR: 2.01 (95% CI, 1.64-2.47).
    • Multiple myeloma, pooled SIR: 1.48 (95% CI, 1.02-2.14).
    • Cervix, pooled SIR: 1.56 (95% CI, 1.29-1.88).
    • Vagina/vulva, pooled SIR: 3.48 (95% CI, 2.69-4.50).
    • Renal, pooled SIR: 2.10 (95% CI, 1.11-3.96).
    • Bladder, pooled SIR: 1.86 (95% CI, 1.16-2.99).
    • Esophagus, pooled SIR: 1.64 (95% CI, 1.43-1.87).
    • Gastric, pooled SIR: 1.31 (95% CI, 1.04-1.63).
    • Hepatobiliary, pooled SIR: 2.37 (95% CI, 1.67-3.38).
    • Lung, pooled SIR: 1.62 (95% CI, 1.40-1.87).
    • Larynx, pooled SIR: 2.90 (95% CI, 1.82-4.62).
    • Oropharynx, pooled SIR: 1.52 (95% CI, 1.00-2.30).
    • Nonmelanoma skin cancer, pooled SIR: 1.41 (95% CI, 1.07-1.87).

Limitations

  • Observational design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit